| Zolbetuximab plus mFOLFOX6 in patients with CLDN18. 2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction … K Shitara, F Lordick, YJ Bang, P Enzinger, D Ilson, MA Shah, ... The Lancet 401 (10389), 1655-1668, 2023 | 177 | 2023 |
| The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta‐analysis M Oh, N Alkhushaym, S Fallatah, A Althagafi, R Aljadeed, Y Alsowaida, ... The Prostate 79 (8), 880-895, 2019 | 148 | 2019 |
| BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis M Oh, A McBride, S Yun, S Bhattacharjee, M Slack, JR Martin, J Jeter, ... JNCI: Journal of the National Cancer Institute 110 (11), 1178-1189, 2018 | 132 | 2018 |
| Zolbetuximab plus CAPOX in CLDN18. 2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial MA Shah, K Shitara, JA Ajani, YJ Bang, P Enzinger, D Ilson, F Lordick, ... Nature medicine 29 (8), 2133-2141, 2023 | 88 | 2023 |
| Economic evaluation of talimogene laherparepvec plus ipilimumab combination therapy vs ipilimumab monotherapy in patients with advanced unresectable melanoma AR Almutairi, NS Alkhatib, M Oh, C Curiel-Lewandrowski, HM Babiker, ... JAMA dermatology 155 (1), 22-28, 2019 | 32 | 2019 |
| Prevalence, patterns, and predictors of depression treatment among community-dwelling elderly individuals with dementia in the United States S Bhattacharjee, YM Oh, EM Reiman, WJ Burke The American Journal of Geriatric Psychiatry 25 (7), 803-813, 2017 | 25 | 2017 |
| Exposure to proton pump inhibitors and risk of pancreatic cancer: a meta-analysis N Alkhushaym, AR Almutairi, A Althagafi, SB Fallatah, M Oh, JR Martin, ... Expert opinion on drug safety 19 (3), 327-334, 2020 | 18 | 2020 |
| Sensorineural hearing loss with macrolide antibiotics exposure: a meta-analysis of the association YS Alsowaida, AS Almulhim, M Oh, B Erstad, I Abraham International Journal of Pharmacy Practice 29 (1), 21-28, 2021 | 17 | 2021 |
| Cost-effectiveness of novel antiandrogens (AAs) for treatment of nonmetastatic castrate-resistant prostate cancer (nmCRPC). IB Riaz, A Almutairi, DK Lang, N Asghar, A Riaz, Y Yao, QUAR Sipra, ... Journal of Clinical Oncology 38 (15_suppl), 5583-5583, 2020 | 6 | 2020 |
| Network meta-analysis (NMA) comparing the efficacy of enzalutamide versus apalutamide, darolutamide, and bicalutamide for treatment of nonmetastatic (nm) castration-resistant … TM Beer, F Saad, CN Sternberg, MHA Hussain, A Ganguli, HS Bhadauria, ... Journal of Clinical Oncology 39 (6_suppl), 101-101, 2021 | 4 | 2021 |
| The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention M Oh, A McBride, S Bhattacharjee, M Slack, J Jeter, I Abraham Expert Review of Pharmacoeconomics & Outcomes Research 23 (3), 309-316, 2023 | 3 | 2023 |
| Cost analysis of adjunctive hydrocortisone therapy for septic shock: US payer perspective M Oh, AE Patanwala, N Alkhatib, A Almutairi, I Abraham, B Erstad Critical Care Medicine 48 (10), e906-e911, 2020 | 3 | 2020 |
| 1530P Health-related quality of life (hrqol) in patients with claudin-18 isoform 2-positive (CLDN18. 2+) locally advanced (LA) unresectable or metastatic gastric or … F Lordick, E Van Cutsem, K Shitara, RH Xu, JA Ajani, MA Shah, M Oh, ... Annals of Oncology 34, S860-S861, 2023 | 2 | 2023 |
| Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment M Oh, A McBride, S Bhattacharjee, M Slack, J Jeter, I Abraham Expert Review of Pharmacoeconomics & Outcomes Research 23 (3), 297-307, 2023 | 2 | 2023 |
| Patient preferences for treatment and outcomes in hormone-sensitive prostate cancer (HSPC). DJ George, A Ganguli, AK Morgans, BF Tombal, SJ Hotte, H Suzuki, ... Journal of Clinical Oncology 40 (16_suppl), e18757-e18757, 2022 | 2 | 2022 |
| Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer B Tombal, CN Sternberg, M Hussain, A Ganguli, Y Li, R Sandin, ... ESMO open 7 (3), 100510, 2022 | 2 | 2022 |
| Discrete-Choice Experiment to Understand the Preferences of Patients with Hormone-Sensitive Prostate Cancer in the USA, Canada, and the UK JM Gonzalez, A Ganguli, AK Morgans, BF Tombal, SJ Hotte, H Suzuki, ... The Patient-Patient-Centered Outcomes Research 16 (6), 607-623, 2023 | 1 | 2023 |
| The economic value of knowing BRCA status: BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer M Oh, A McBride, S Bhattacharjee, M Slack, J Jeter, I Abraham Expert Review of Pharmacoeconomics & Outcomes Research 23 (3), 317-325, 2023 | 1 | 2023 |
| Meta-analysis of same-day pegfilgrastim administration stratified by myelotoxic febrile neutropenia risk and tumor type N Alrawashdh, A McBride, M Oh, N Alkhatib, C Lee, J Martin, ... Journal of the Advanced Practitioner in Oncology 13 (8), 796, 2022 | 1 | 2022 |
| Cost-effectiveness of novel antiandrogens (AAs) for treatment of nonmetastatic castrate-resistant prostate cancer (nmCRPC). I Bin Riaz, A Almutairi, DK Lang, N Asghar, A Riaz, Y Yao, QUAR Sipra, ... JOURNAL OF CLINICAL ONCOLOGY 38 (15), 2020 | 1 | 2020 |
